MedTrace Logo

Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis

NCT02963727 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-04-28

No results posted yet for this study

Summary

Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) will be injected in patients diagnosed with Knee osteoarthrosis

Conditions

  • Knee Osteoarthrosis

Interventions

BIOLOGICAL

Wharton Jelly derived mesenchymal stem cell

Intra-articular Wharton Jelly derived mesenchymal stem cell injection.

Sponsors & Collaborators

  • Hanan Jafar

    lead OTHER

Principal Investigators

  • Abdallah Awidi, MD · Cell Therapy Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
42 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-27
Primary Completion
2021-10-31
Completion
2021-12-31

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02963727 on ClinicalTrials.gov